Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS

Neurology. 2013 Aug 27;81(9):850-2. doi: 10.1212/WNL.0b013e3182a2cc4a. Epub 2013 Jul 24.


Glatiramer acetate (GA), a synthetic copolymer, is a frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Probable autoimmune hepatotoxicity during GA treatment has been reported,(1-4) but GA hepatotoxicity in the absence of positive autoimmune markers has not previously been described. Here, we report GA-induced hepatotoxicity in a pediatric patient with multiple sclerosis (MS).

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / adverse effects*
  • Adjuvants, Immunologic / therapeutic use
  • Adolescent
  • Biopsy
  • Chemical and Drug Induced Liver Injury / pathology*
  • Disease Progression
  • Female
  • Glatiramer Acetate
  • Humans
  • Multiple Sclerosis, Relapsing-Remitting / diagnosis
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Peptides / adverse effects*
  • Peptides / therapeutic use
  • Treatment Outcome


  • Adjuvants, Immunologic
  • Peptides
  • Glatiramer Acetate